e-Therapeutics has partnering relationships with companies that have complementary expertise or resources in compound libraries, high-throughput screening, chemogenomics, and clinical research. The company is exploring further relationships in these areas, and in the areas of marketing and distribution of branded generic drugs in less familiar indications which have been emphasised by e-Therapeutics’ research.

Alliance with Khandelwell

e-Therapeutics has an alliance with Khandelwal Laboratories, a producer of pharmaceuticals and active pharmaceutical ingredients. KLab has one of the largest ranges of oncology formulations in India. The company markets a variety of generic products for a range of therapeutic areas, including oncology, anti-infectives, NSAIDs, and corticosteroids. Its products are manufactured in KLab’s WHO GMP facilities.

Alliance with Veeda Clinical Research

e-Therapeutics has an alliance with Veeda, a leading clinical research organisation in India. Veeda uniquely have a facility in the UK as well as in India, and operate clinical trials to comply with western regulatory standards. This relationship offers the ability to have e-Therapeutics’ drugs developed rapidly and cost effectively at the highest quality and ethical standards.

Alliance with CCTT

e-Therapeutics has an alliance with CCTT, for cardiovascular testing. CCTT was founded by Dr Derek Terrar, based at the Department of Pharmacology at Oxford University, who is an internationally recognised authority on cardiovascular medicine and function. This expertise is important both to assessment and development of specific cardiovascular candidates, and because cardiovascular complications are a frequent cause of the failure of drug development candidates elsewhere in the industry.

Collaboration with UK Health Protection Agency

e-Therapeutics is beginning a collaboration with the United Kingdom Health Protection Agency for testing e-Therapeutics’ drug candidates against resistant strains of bacteria, and resistant mycobacteria.